Morepen Lab to sell anti-asthmatic drug in Europe and North America

India Infoline News Service | Mumbai | February 10, 2016 12:40 IST

The company eyes Rs. 100 crore global turnover in 2016-17 from this product.

Morepen Laboratories, a mid-size pharma company, is all set to sell anti-asthmatic drug Montelukast in European and North American markets. The company eyes Rs. 100 crore global turnover in 2016-17 from this product.

Sushil Suri, Chairman and Managing Director, Morepen Lab said, “We are tying up in European and North American markets for supplies to ANDA (abbreviated new drug application) holders for the sale of Montelukast Sodium. The bulk drug has contributed Rs. 48 crore to the company’s total income in the nine-month period.”


***Note: This is a NSE Chart

 

Advertisements

  • Save upto Rs.2.67 lakh with Pradhan Mantri Awas Yojana ...Know more
  • Now Save Rs.3150 on your Demat Account ...Click here
  • Now get IIFL Personal Loan in just 8* hours...APPLY NOW!
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.